Zacks Investment Research upgraded shares of H Lundbeck A/S (OTCMKTS:HLUYY) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. Zacks Investment Research currently has $62.00 target price on the stock.
According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “
Separately, Deutsche Bank AG lowered shares of H Lundbeck A/S from a hold rating to a sell rating in a research report on Friday, July 28th.
H Lundbeck A/S Company Profile
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for H Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.